Evofem Biosciences Company

Lithera is developing products for aesthetic medicine to address both medical and lifestyle indications. Its lead product is an injectable treatment to achieve local, selective fat tissue reduction (pharmaceutical lipoplasty). Using FDA registered drugs proven safe and effective in other indications, its product targets and stimulates natural fat metabolism and achieves non-ablative, non-surgical fat tissue reduction in specific locations.

Connections from

Technology: Specific disorder-related
Industry: Treatment range
Headquarters: San Diego, USA
Founded Date: 01.01.2009
Employees Number: 101-250
Funding Status: IPO
Investors Number: 11
Total Funding: $192 800 000
Estimated Revenue: $1-10 Mn
Last Funding Date: 15.10.2020
Last Funding Type: Post-IPO Debt

Visit Website
info@evofem.com
https://twitter.com/evofembio?
Register and Claim Ownership